| Citation: |
ZHANG Tongxian, ZHANG Wei, LIU Fen, LIU Han, NIU Yun. Expressions of CD20+B and CD3+T Lymphocytes in Infiltrating Ductal Carcinoma and Medullary Carcinoma and Their Relationships with Prognosis[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 463-467. DOI: 10.3971/j.issn.1000-8578.2013.05.013
|
| [1] |
Kuroda H, Tamaru J, Sakamoto G, et al. Immunophenotype of lymphocytic infiltrationin medullary carcinoma of the breast[J].Virchows Arch, 2005,446(1):10-4.
|
| [2] |
Lim KH, Telisinghe PU, Abdullah MS, et al. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast[J]. Cancer Immun, 2010,10:3.
|
| [3] |
Coughlin CM, Vance BA, Grupp SA, et al. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy[J]. Blood, 2004, 103(6):2046-54.
|
| [4] |
Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer[J]. Clin Cancer Res, 2008, 14(16): 5220-7.
|
| [5] |
de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent[J]. Cancer Cell, 2005, 7(5):411-23.
|
| [6] |
Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword[J]. Cancer Cell, 2005, 7(5):403-5.
|
| [7] |
Lakhani SR, Ellis OI, Schnitt SJ, et al. WHO classification of tumors of the breast[M]. Lyon: Editors IARC Press, 2012, 34-47.
|
| [8] |
Wang ZK, Yang B, Liu H, et al. Regulatory T cells increase in breast cancer and in stage IV breast cancer[J]. Cancer Immunol Immunother, 2012, 61(6):911-6.
|
| [9] |
Kavalar R, Sarcevic B, Spagnoli GC, et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study[J]. Virchows Arch，2001,439(2):127-31.
|
| [10] |
Gilboa E. The promise of cancer vaccines[J]. Nat Rev Cancer, 2004, 4(5):401-11.
|
| [11] |
Schmidt M, Bhm D, von Trne C, et al.The humoral immune system has a key prognostic impact in node-negative breast cancer[J]. Cancer Res,2008 ,68(13):5405-13.
|
| [12] |
Menegaz RA, Michelin MA, Etchebehere RM, et al.Peri- and intratumoral T and B lymphocytic infiltration in breast cancer [J]. Eur J Gynaecol Oncol,2008,29(4):321-6.
|
| [13] |
Mahmoud SM, Lee AH, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast[J]. Breast Cancer Res Treat, 2012,32(2):545-53.
|
| [14] |
Nelson BH.CD20+ B cells: the other tumor-infiltrating lymphocytes[J].J Immunol,2010,185(9):4977-82.
|
| [15] |
Li Q, Lao X, Pan Q, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression[J]. Clin Cancer Res,2011,17(15):4987-95.
|
| [16] |
Andre F, Dieci MV, Dubsky P, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer [J].Clin Cancer Res,2013,19(1):28-33.
|
| [17] |
Yamaguchi R, Tanaka M, Yano A, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer[J]. Hum Pathol, 2012,43(10):1688-94.
|
| [18] |
West NR, Milne K, Truong PT, et al. T umor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer[J]. Breast Cancer Res,2011,13(6):R126.
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: